



August 1, 2012

SBI Pharmaceuticals Co., Ltd

Notice on the Appointment of a New Director

SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), an affiliate company of SBI Holdings, Inc. , is engaged in research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA). SBI Pharmaceuticals hereby announces that a new director was elected and appointed at extraordinary shareholders’ meeting held on August 1, 2012.

1. The name of the new director

Riyadh Rehani. Ph.D.

2. The carrier of the new director

After the acquisition of his doctoral degree in environmental toxicology at University of Wisconsin, Dr. Rehani had been engaged in the academic research at the university. As his contribution toward many study programs about the fate of toxic chemicals in the environment was highly appreciated, he was appointed as the Honorary Fellow of University of Wisconsin in 1989. At the same year, he joined to Covance Inc. and experienced numerous projects as a professional of toxicology. He had managed all concerning to drug development as a Program Manager from 2005.

SBI Pharmaceuticals Co., Ltd. highly appreciates Dr. Rehani’s high expertise and the experience of numerous international drug development projects. We expect his join will help to advance our drug development projects.

*Covance Inc.

Covance Inc. is a Contract Research Organization (CRO) headquartered in US. It is the world’ s No.1 Company in the number of clinical study application of new drugs. It supports the drug development in many countries represented by Japan, US, and Europe.

For further information, please contact:

SBI Pharmaceuticals Co., Ltd.: Corporate Planning Dept., Tel: +81 3 6229 0095